Can a common blood pressure drug protect the placenta in Early-Onset preeclampsia?

NCT ID NCT07738562

Disease control Sponsor: Hadassah Medical Organization Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This pilot study tests whether adding dipyridamole, an approved drug that improves blood flow, to standard care is feasible and safe for pregnant women with early-onset preeclampsia. The trial will enroll 15 hospitalized women between 26 and 34 weeks of pregnancy with high levels of certain placental markers. Researchers will measure how the drug is processed in the body, its side effects, and its effects on placental health, aiming to gather data for a larger future trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Dipyridamole (oral tablets)
What this could lead to: If successful, this could pave the way for a larger trial testing whether dipyridamole can slow the placental damage in early-onset preeclampsia, potentially delaying delivery and improving outcomes for mothers and babies.
What could go wrong: This is a small pilot study focused on feasibility and safety, not effectiveness. The drug may not show clear benefits, and there are risks of side effects or complications in a high-risk pregnancy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Age ≥ 18 years * Singleton pregnancy * Established early-onset preeclampsia, with or without severe features, with gestational age from 26+0 to 33+6 weeks at enrollment, confirmed by best obstetric estimate * Hospitalization for maternal and/or fetal surveillance * Expectant management deemed appropriate by the treating clinical team at the time of enrollment * sFlt-1/PlGF ratio ≥85 at screening * Confirmed viable fetus without a known or suspected major structural or chromosomal anomaly * Baseline platelet count ≥100,000/µL * Ability to provide written informed consent Exclusion Criteria * Immediate indication for delivery at time of screening, including uncontrolled severe hypertension, eclampsia, HELLP syndrome, or severe fetal compromise * Active maternal bleeding or clinically significant bleeding disorder * Therapeutic-dose anticoagulation (e.g., enoxaparin \>1 mg/kg/day) * Known hypersensitivity or contraindication to dipyridamole * Multiple gestation * Known major fetal anomaly or chromosomal abnormality * Baseline thrombocytopenia, platelet count \<100,000/µL * Hemodynamically significant maternal cardiac disease * Significant maternal comorbidity that, in the investigator's judgment, precludes safe participation * Inability to comply with study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension ,pregnancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertension, pregnancy-induced preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension ,pregnancy Preeclampsia (PE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Can a common blood pressure drug protect the placenta in Early-Onset preeclampsia?

What the study statuses mean